Cargando…
Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer
Until recently, the prognosis and treatment of patients with advanced-stage squamous cell lung cancers have been limited. An improvement in the understanding of the role of the immune system in tumor immunosurveillance has led to the development of the programmed death-1 (PD-1) immune checkpoint inh...
Autores principales: | Ang, Yvonne LE, Lim, Joline SJ, Soo, Ross A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892831/ https://www.ncbi.nlm.nih.gov/pubmed/27313464 http://dx.doi.org/10.2147/OTT.S84356 |
Ejemplares similares
-
Nivolumab in the treatment of metastatic squamous non-small cell lung
cancer: a review of the evidence
por: Lim, Joline S. J., et al.
Publicado: (2016) -
Nivolumab in Metastatic Non–Small Cell Lung Cancer
por: Deel, Andrea
Publicado: (2016) -
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
por: Oro-Ayude, Marcos, et al.
Publicado: (2020) -
Bilateral uveitis associated with nivolumab therapy for metastatic non-small cell lung cancer
por: Dermarkarian, Christopher R., et al.
Publicado: (2020) -
Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
por: Rothwell, Ben, et al.
Publicado: (2020)